Biotech Top Losers: Progenics Pharmaceuticals (NASDAQ:PGNX), Oramed Pharmaceuticals (NASDAQ:ORMP), Prosensa Holding NV (NASDAQ:RNA), Marina Biotech (MRNA)
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced that Mark R. Baker, CEO of Progenics, will present at the 16th Annual BIO CEO & Investor Conference which will be held February 10th and 11th at the Waldorf Astoria Hotel in New York City. The presentation will take place on Monday, February 10th at 3:00 PM EST. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock opened at $4.66 in last trading session, and closed at $4.39, trading in the range of $4.28 – $4.74. The stock showed a negative weekly performance of -15.58%.
Analysts at Aegis lifted their target price on shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from $30.00 to $35.00 in a research report issued to clients and investors on Thursday, Stock Ratings Network reports. The firm currently has a “buy” rating on the stock. Aegis’ price objective would indicate a potential upside of 58.44% from the company’s current price. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) shares closed at $13.97 on last trade day, by gaining / losing -13.82%. Stock 52 week range is $5.00 – $31.73. Company’s market capitalization is $136.34 billion.
Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Prosensa Holding N.V. (NASDAQ: RNA) violated state or federal laws. Prosensa is a Dutch biotechnology company engaged in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders. Prosensa Holding NV (NASDAQ:RNA) stock decreased -5.72% and finished the last session at $5.77. The EPS of the stock remained -0.65. Company’s market capitalization is $207.16 billion.
Marina Biotech, Inc. (OTCMKTS:MRNA) is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference (RNAi) and blocking messenger RNA (mRNA) translation. Marina Biotech, Inc. (OTCMKTS:MRNA) stock opened at $0.98 in last trading session and closed at $0.930. The 52 week range of the stock is $0.18 – $1.10 and the day range was $0.86 – $1.00.